Patent intelligence · AU
AU 2023257308
USES OF FARNESOID X RECEPTOR AGONISTS
USES OF FARNESOID X RECEPTOR AGONISTS
Patent details — AU 2023257308
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Oct 10, 2024
- Expiration
- Oct 5, 2044
- Applicant
- ALFASIGMA S P A [IT]
- CPC classes
- A61K 31/ 015 A I, A61K/31573, A61K/31575, A61K/4506
Quick answer
AU 2023257308 (USES OF FARNESOID X RECEPTOR AGONISTS) is held by ALFASIGMA S P A [IT]. Status: granted. Granted Oct 10, 2024. Expires Oct 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALFASIGMA S P A [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 015 A I, A61K/31573, A61K/31575, A61K/4506, A61P/116
More from ALFASIGMA S P A [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026027669
BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
IT 202300012522
FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
IT 202300001434
PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.
granted -
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
granted -
IT 202200013882
PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.
granted
Frequently asked questions
What is US patent 2023257308?
AU 2023257308 (USES OF FARNESOID X RECEPTOR AGONISTS) is held by ALFASIGMA S P A [IT]. Status: granted. Granted Oct 10, 2024. Expires Oct 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2023257308?
ALFASIGMA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2023257308 expire?
Our index shows an expiration date of Oct 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.